Talimogene laherparepvec with pembrolizumab for treating unresectable or metastatic melanoma [ID3856]
Discontinued
Reference number: GID-TA10836
Following on from information provided to NICE by the company in March 2021, the appraisal of Talimogene laherparepvec with pembrolizumab for treating unresectable or metastatic melanoma [ID3856] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.